Your browser is no longer supported. Please, upgrade your browser.
Settings
CNAT Conatus Pharmaceuticals Inc. daily Stock Chart
CNAT [NASD]
Conatus Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-0.99 Insider Own3.41% Shs Outstand29.04M Perf Week-2.91%
Market Cap164.66M Forward P/E26.50 EPS next Y0.21 Insider Trans0.00% Shs Float28.98M Perf Month10.10%
Income-25.00M PEG- EPS next Q0.02 Inst Own40.30% Short Float8.23% Perf Quarter10.96%
Sales17.80M P/S9.25 EPS this Y-1.20% Inst Trans59.96% Short Ratio4.24 Perf Half Y28.86%
Book/sh1.22 P/B4.65 EPS next Y146.70% ROA-33.60% Target Price18.00 Perf Year171.29%
Cash/sh3.04 P/C1.87 EPS next 5Y38.00% ROE-96.50% 52W Range1.45 - 9.40 Perf YTD7.59%
Dividend- P/FCF8.85 EPS past 5Y35.60% ROI-130.80% 52W High-39.68% Beta1.31
Dividend %- Quick Ratio2.80 Sales past 5Y- Gross Margin- 52W Low290.15% ATR0.26
Employees25 Current Ratio2.80 Sales Q/Q- Oper. Margin- RSI (14)49.75 Volatility4.45% 4.67%
OptionableYes Debt/Eq0.37 EPS Q/Q35.80% Profit Margin- Rel Volume0.31 Prev Close5.60
ShortableYes LT Debt/Eq0.37 EarningsAug 02 AMC Payout- Avg Volume563.13K Price5.67
Recom1.70 SMA201.64% SMA500.42% SMA2007.06% Volume174,371 Change1.25%
Mar-16-17Reiterated Stifel Buy $7 → $9
Dec-20-16Reiterated Stifel Buy $5 → $7
Dec-20-16Reiterated H.C. Wainwright Buy $9 → $18
Nov-09-16Reiterated Stifel Buy $6 → $5
Jul-01-16Resumed ROTH Capital Buy
Nov-05-15Reiterated Stifel Buy $11 → $9
Sep-22-15Initiated H.C. Wainwright Buy $15
Apr-28-15Initiated Brean Capital Buy $13
Mar-17-15Resumed ROTH Capital Buy $15
Mar-12-15Reiterated Stifel Buy $13 → $11
Jan-09-15Reiterated ROTH Capital Buy $19 → $12
Oct-21-14Initiated MLV & Co Buy $16
Aug-14-14Reiterated Stifel Buy $14 → $13
Aug-19-13Initiated Stifel Buy $16
Sep-19-17 01:53PM  Hedge fund manager shuts firm to explore run for Connecticut governor Reuters
Sep-08-17 08:26AM  Conatus (CNAT) Up 7% Since Earnings Report: Can It Continue? Zacks
Aug-31-17 04:05PM  Conatus Pharmaceuticals Appoints Keith W. Marshall as Executive Vice President, Chief Operating Officer and Chief Financial Officer GlobeNewswire
Aug-29-17 04:05PM  Conatus to Present at Rodman & Renshaw Global Investment Conference GlobeNewswire
Aug-21-17 05:47PM  Will Conatus Key Candidate Emricasan Drive Long-Term Growth? Zacks
Aug-14-17 04:05PM  Conatus Announces Completion of Enrollment in ENCORE-NF Phase 2b Clinical Trial of Emricasan in Patients with NASH Fibrosis GlobeNewswire
Aug-03-17 04:41PM  Conatus (CNAT) Q2 Loss Narrows Y/Y, Revenues Beat Estimates Zacks -7.72%
01:05AM  Conatus reports 2Q loss Associated Press
Aug-02-17 04:05PM  Conatus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Program Updates GlobeNewswire
10:00AM  Investor Network: Conatus Pharmaceuticals Inc. to Host Earnings Call ACCESSWIRE
Jul-26-17 04:05PM  Conatus Pharmaceuticals to Report Second Quarter 2017 Financial Results GlobeNewswire
10:29AM  What's in Store for Conatus (CNAT) this Earnings Season? Zacks
Jul-07-17 08:50AM  Why Conatus Pharma Wins With Newest Licensing Agreement 24/7 Wall St. +5.34%
Jul-06-17 04:05PM  Conatus Announces Effectiveness of Exclusive License for Global Development and Commercialization of Emricasan with Receipt of $7 Million Payment GlobeNewswire
Jun-29-17 12:48PM  H.C. Wainwright Bullish on Conatus Pharmaceuticals Inc (CNAT) on Back of Orphan Drug Designation for IDN-7314 SmarterAnalyst +10.71%
Jun-27-17 10:52AM  Company News for June 27, 2017 Zacks
08:50AM  Conatus's PSC Candidate Gets Orphan Designation in the U.S. Zacks
08:00AM  Today's Research Reports on Stocks to Watch: Moleculin Biotech and Conatus Pharmaceuticals Accesswire
Jun-26-17 07:00AM  FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC GlobeNewswire +9.61%
Jun-16-17 07:00AM  Conatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference GlobeNewswire
Jun-08-17 09:54AM  Conatus (CNAT) Down 33.1% Since Earnings Report: Can It Rebound? Zacks
May-16-17 04:05PM  Conatus Announces Completion of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares GlobeNewswire
May-12-17 08:00AM  Today's Research Reports on Stocks to Watch: Conatus Pharmaceuticals and Sangamo Therapeutics Accesswire
May-11-17 09:02AM  Conatus Announces Pricing of Public Offering of Common Stock GlobeNewswire -21.51%
May-10-17 04:01PM  Conatus Announces Proposed Public Offering of Common Stock GlobeNewswire
May-05-17 11:06AM  Conatus (CNAT) Q1 Loss Narrows Y/Y, Revenues Beat Estimates Zacks
08:15AM  Blog Coverage: Novartis Exercises Option for Global Development and Commercialization of Conatus Pharmaceuticals' Drug Emricasan Accesswire
05:02AM  Conatus reports 1Q loss Associated Press
May-04-17 04:05PM  Conatus Pharmaceuticals Reports First Quarter 2017 Financial Results and Program Updates GlobeNewswire
01:51AM  Novartis exercises option with Conatus for NASH product Reuters
01:15AM  Conatus Announces Exercise of License Option for Global Development and Commercialization of Emricasan Following Notice of Initiation of Phase 2b ENCORE-LF Clinical Trial in NASH Cirrhosis GlobeNewswire
May-02-17 09:58AM  Can Conatus Pharma (CNAT) Deliver a Beat in Q1 Earnings? Zacks
Apr-27-17 04:05PM  Conatus Pharmaceuticals to Report First Quarter 2017 Financial Results GlobeNewswire +6.17%
08:35AM  Conatus (CNAT) Catches Eye: Stock Moves Up 10% in Session Zacks
07:30AM  Today's Research Reports on Stocks to Watch: Conatus Pharmaceuticals and Sonus Networks Accesswire
Apr-26-17 07:00AM  Conatus (CNAT) Up 57.7% Since Earnings Report: Can It Continue? Zacks +9.84%
Apr-21-17 02:00AM  Conatus Posters at EASL Meeting Address MELD Score Dynamics and Outcomes in Decompensated Liver Cirrhosis Patients, Including NASH Patients, Awaiting Liver Transplantation GlobeNewswire
Apr-17-17 08:40AM  Are Options Traders Betting on a Big Move in Conatus Pharmaceuticals (CNAT) Stock? Zacks
Apr-03-17 09:30AM  Conatus Pharmaceuticals and MannKind Look Forward to Promoting Their Brand Accesswire
Mar-30-17 08:46AM  Galectin Shares Upgraded To Buy; NASH-CX Results In December A 'Major Stock Catalyst' Benzinga +17.93%
Mar-27-17 07:30AM  Conatus to Present at Upcoming Investor Conferences GlobeNewswire
Mar-23-17 01:04PM  CONATUS PHARMACEUTICALS INC. Financials
Mar-21-17 04:06PM  CONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and -6.55%
Mar-16-17 04:09PM  CONATUS PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report -6.52%
11:11AM  Conatus Pharma (CNAT) Incurs Wider-than-Expected Loss in Q4 Zacks
Mar-15-17 04:46PM  Conatus reports 4Q loss Associated Press +6.05%
04:07PM  CONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:05PM  Conatus Pharmaceuticals Reports 2016 Financial Results and Program Updates GlobeNewswire
07:07AM  Q4 2016 Conatus Pharmaceuticals Inc Earnings Release - After Market Close
Mar-08-17 04:05PM  Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Feb-28-17 07:24AM  Conatus Pharmaceuticals (CNAT) Q4 Earnings: What's in Store? Zacks
Feb-17-17 04:06PM  CONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers
Feb-16-17 04:06PM  CONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fin
Feb-07-17 07:33AM  CONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers
07:30AM  Conatus Pharmaceuticals Appoints William R. LaRue as Independent Board Member GlobeNewswire
Feb-06-17 07:30AM  Conatus to Present at BIO CEO & Investor Conference GlobeNewswire +17.01%
Feb-02-17 04:05PM  Conatus Pharmaceuticals Promotes Daniel L. Ripley to Senior Vice President, Business Development, Program and Alliance Management GlobeNewswire
Feb-01-17 04:06PM  CONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jan-26-17 04:06PM  CONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Termination of a Material Definitive Agreement -5.18%
Jan-13-17 06:45AM  Short Interest In Conatus Pharmaceuticals Surges
Jan-12-17 08:38AM  Henry Schein Hurt by Higher Costs, Lacks Growth Drivers
07:07AM  Walgreens Teams Up with Fedex to Boost Retail Performance
06:46AM  NuVasive at 52-Week High on Preliminary Results, MHLW Nod
Jan-11-17 10:31AM  Can The Uptrend Continue for Conatus (CNAT)?
07:13AM  Align Poised On Global Expansion & Invisalign Teen Growth
Dec-30-16 11:47AM  Traders Are Cleaning Out Their Portfolios
Dec-29-16 01:10PM  Conatus Pharmaceuticals Significant Joint-Venture Review and Analysis of Third Quarter 2016 Results Accesswire
Dec-28-16 09:00AM  Are Options Traders Betting on a Big Move in Conatus Pharmaceuticals (CNAT) Stock? -13.58%
Dec-23-16 11:39AM  Conatus Pharmaceuticals, Inc. :CNAT-US: Earnings Analysis: Q3, 2016 By the Numbers : December 23, 2016 +17.51%
08:40AM  Options Traders Expect Huge Moves in Conatus Pharmaceuticals (CNAT) Stock
Dec-21-16 10:10AM  Company News for December 21, 2016 -8.67%
09:25AM  Biotech Stock Roundup: Conatus Soars on Novartis Deal, Early FDA Nod for Clovis Drug
09:15AM  Today's Reports on Biotech Movers ACADIA Pharmaceuticals and Conatus Pharmaceuticals Accesswire
Dec-20-16 12:00PM  Banking Sector Leading Rally in U.S. Markets +141.33%
10:46AM  General Mills falls on miss, BlackBerry's profit surprise, Facebook faces EU probe over WhatsApp merger
10:37AM  Novartis AG (ADR) (NVS) Agrees To $50 Million Deal With Conatus Pharmaceuticals Inc (CNAT) at Insider Monkey
10:30AM  Conatus Pharma Doubles On Novartis NASH Liver Drug Licensing Deal
08:53AM  Conatus Stock Up on Liver Drug Collaboration with Novartis
08:50AM  Conatus More Than Doubles on Key License Collaboration Agreement
08:15AM  Dow closes in on 20K, Apple talks to India and Uber losses mount
05:54AM  Dow futures point to slow march higher toward key 20,000 mark at MarketWatch
Dec-19-16 10:02PM  Futures Point North; Asia Mixed, Despite European Attacks
05:21PM  Conatus shares skyrocket after Novartis license deal at MarketWatch
04:31PM  CONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or P
04:30PM  Conatus Announces Exclusive Worldwide Option, Collaboration and License Agreement Covering Development and Commercialization of Emricasan GlobeNewswire
Nov-14-16 08:00AM  Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting GlobeNewswire
Nov-09-16 08:09AM  Conatus (CNAT) Reports Narrower-than-Expected Loss in Q3 +7.05%
07:30AM  Conatus Pharmaceuticals to Present at Stifel 2016 Healthcare Conference GlobeNewswire
Nov-08-16 04:28PM  Conatus reports 3Q loss
04:07PM  CONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:05PM  Conatus Pharmaceuticals Reports Third Quarter 2016 Financial Results and Program Updates GlobeNewswire
07:07AM  Q3 2016 Conatus Pharmaceuticals Inc Earnings Release - After Market Close
Nov-03-16 07:30AM  Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis GlobeNewswire -5.06%
Nov-01-16 04:05PM  Conatus Pharmaceuticals to Report Third Quarter 2016 Financial Results GlobeNewswire -10.73%
Oct-31-16 09:11AM  Conatus (CNAT) Q3 Earnings: What's in Store for the Stock?
Oct-04-16 10:34AM  Why Facebook, Netflix, and Three Other Stocks Are in Spotlight Today at Insider Monkey +6.12%
Oct-03-16 06:13PM  After-hours buzz: QCOM, CNAT & more at CNBC
04:12PM  Conatus Pharmaceuticals Announces Acceptance of Emricasan Abstracts for AASLD Annual Meeting GlobeNewswire
Sep-22-16 03:06PM  Why Collegium Pharmaceuticals Inc (COLL), Galmed Pharmaceuticals Ltd (GLMD) and Three Other Stocks Are Registering Significant Gains Today at Insider Monkey
09:08AM  5 Biotech Stocks to Watch as Interest in NASH Increases
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. The company was founded in 2005 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cashion CharlesSVP, Finance, CFO and Sec.Jan 09Option Exercise0.9942,42442,00042,424Jan 11 04:01 PM
Mento Steven JPresident, CEO & DirectorDec 20Option Exercise1.2141,41450,09141,414Dec 22 04:04 PM
Van Wart HaroldDirectorOct 27Option Exercise0.2518,1814,54518,181Oct 31 04:37 PM